ASCO 2026 marked an important transition in oncology. Rather than showcasing isolated advances, the meeting demonstrated how precision medicine, targeted therapies, immunotherapy, individualized treatments and emerging technologies are increasingly converging to reshape both cancer care and clinical development. This webinar explores what those developments mean for oncology clinical trial strategy, operational planning and patient access.
Promising data challenged long-standing assumptions from targeting previously “undruggable” cancer biology and advancing personalized cancer vaccines to using genomic information to safely reduce treatment intensity. At the same time, bispecific antibodies, novel immune-based approaches and AI-enabled tools continued to move closer to routine clinical application.
However, scientific progress alone does not guarantee successful development or patient access.
In this webinar, oncology experts will examine key highlights from ASCO 2026 through three complementary perspectives: the CRO and sponsor, the clinical research site and the principal investigator. The discussion will explore how emerging evidence may influence development strategies, protocol design, biomarker and patient-selection approaches, site feasibility, recruitment, treatment delivery, safety oversight, data quality and the overall patient experience.
By bringing strategic, operational and clinical viewpoints together, the webinar will move beyond the headlines to consider what these advances mean in practice and what sponsors, sites and investigators must do differently to translate increasingly personalized and complex oncology science into efficient clinical trials and meaningful patient benefits.
Register for this webinar to learn how ASCO 2026 oncology data may influence clinical trial strategy, protocol design and patient selection.
Speakers
(Moderator) Dannelle Palmer, MBA, Chief of Staff, Humaneva
Dannelle Palmer has three decades of global clinical development experience in pharmaceuticals, biotechnologies and global CRO organizations, leading clinical research teams with an emphasis on enhancing the performance and efficiency of oncology clinical research. Dannelle’s expertise and experience range from clinical development planning and regulatory consulting to leading studies from first-in-human through FDA and EMA approval. For the past 15 years, she has held executive-level positions focused on portfolio leadership, strategic leadership and customer-relationship development.
Message Presenter
Scott Schliebner, Chief Operating Officer, P1 Pratia Oncology
Scott is a strategic, innovative and commercially-focused Life Sciences Executive with 30+ years of experience across the biopharma, CRO and life sciences sectors. He thrives while building, transforming and growing clinical research organizations and life sciences companies. With a rare combination of strategic vision, commercial acumen and hands-on operational execution, Scott is an inspirational leader and force multiplier.
Mr. Schliebner currently serves as the Chief Operating Officer at P1 Pratia Oncology, the first global, early-phase and community-based oncology site network. As a Strategic Advisor and Board Member, he also supports early-stage firms leveraging AI-driven platforms and technologies to disrupt and accelerate the clinical drug development process. He regularly speaks on topics such as patient-focused drug development, innovative clinical strategies, novel approaches to clinical development and global drug development market trends. Scott received a Master’s Degree in Public Health from the University of Utah School of Medicine and completed a Graduate Research Fellowship at the National Institutes of Health/NINDS.
Message Presenter
Dr. Julio A. Peguero, President and Executive Chairman, P1 Pratia Oncology; Medical Director of Research, Oncology Consultants, Houston
Dr. Julio A. Peguero is a board-certified Medical Oncologist and Internal Medicine Physician based in Houston, Texas. He serves as Medical Director of Research at Oncology Consultants and President and Executive Chairman of P1 Pratia Oncology, a community-focused early-phase oncology clinical research network. He earned his Medical Degree from the Universidad Autónoma de Guadalajara. Dr. Peguero completed his Internal Medicine residency at the University of Texas Dell Medical School and completed his Medical Oncology fellowship at the University of Texas Medical Branch at Galveston and MD Anderson Cancer Center.
He has served as Principal Investigator in more than 200 clinical trials, including first-in-human studies, and his research has been presented and published at leading conferences and journals in oncology and hematology. He is an early advocate for next-generation sequencing and precision medicine, with a strong commitment to advancing cancer care through innovative research. In addition to his clinical and research leadership, he is dedicated to mentoring and training future physicians through academic and hands-on educational programs.
Message Presenter
Dr. Brandon Fletcher, Medical Affairs, Kapadi
Brandon Fletcher serves as both the Head of Medical Affairs and Cell- and Gene Therapy for Kapadi, the leading academic-based CRO for immuno-oncology and cell & gene therapies. Brandon has served in the industry for 32 years, with a deep focus on immune-oncology cell and gene therapeutics for the past 30 years. She is an adept and empowering leader with expertise in setting innovative strategic direction, medical/scientific currency, education/training, program building, team building and program and project management.
She brings adaptable and actionable expertise and pluripotent industry savvy from multiple academic, hospital, biotech and CRO settings. Brandon is a Biochemist, Drug Development Specialist and Cancer Immunologist by education and training. She was an original collaborator with the NCI’s origination of cancer cell and gene therapeutics and has continued in the field of immune-oncology and genetically modified cell therapeutics since. She co-founded a global philanthropic organization that supports and trains investigators in underserved countries. In addition to her role in Medical Affairs, managing strategy, design and medical/science validity investigator relations, Brandon has served in extensive roles as the Sponsor, Drug Development Consultant, Protocol Writer and in project management and medical science oversight.
Message PresenterWho Should Attend?
This webinar will appeal to:
- Early-phase biotech leaders developing oncology assets
- Clinical Development teams planning first-in-human, Phase I or Phase I/II studies
- Translational and Biomarker Strategy teams working to define patient selection and eligibility
- Regulatory and Medical Affairs professionals supporting oncology trial design and execution
- Program and Portfolio Managers evaluating clinical readiness and operational feasibility
- Operations and study start-up teams looking to improve site activation and enrollment
- Clinical Operations leaders working to identify patients faster and reduce screening failure
- CEOs, CDOs and Founders seeking a practical view of how to execute precision oncology studies more efficiently
- Anyone involved in bringing a biomarker-driven oncology program from design to first patient in, and beyond
What You Will Learn
Attendees will gain insight into:
- Which scientific and clinical developments from ASCO 2026 are most likely to influence oncology drug development and clinical trial strategy?
- How advances in precision medicine, immunotherapy, biomarker-driven treatment and personalized approaches may affect protocol design and patient selection
- What increasingly complex oncology trials mean for sponsors and CROs regarding feasibility, operational planning, risk management and data quality
- How research sites can prepare for evolving requirements around patient identification, treatment delivery, safety monitoring and trial execution
- How principal investigators assess the clinical relevance of emerging data and translate new evidence into meaningful treatment decisions for patients
- Why is closer collaboration among sponsors, CROs, sites and investigators essential for turning scientific innovation into successful clinical development?
Xtalks Partner
Humaneva Group
Humaneva Group: Revolutionizing Oncology Research by a Fully Integrated Approach
Humaneva Group is an integrated clinical research company that brings together specialized research sites, global CRO capabilities, and advanced clinical technology to improve how clinical trials are planned, conducted, and delivered.
Through its interconnected companies (Pratia, Kapadi, and Hyggio), Humaneva connects patients, investigators, research sites, sponsors, and clinical data within a coordinated operating model designed to increase efficiency, data quality, and certainty of execution.
With a particular focus on oncology, Humaneva Oncology combines an embedded oncology site network, purpose-built CRO expertise, patient identification and screening intelligence, and real-time data capabilities. This integrated approach reduces fragmentation, strengthens accountability, and helps sponsors navigate increasingly complex clinical development programs—from early planning and patient access through trial delivery and reliable data generation.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account